what we do?

Rooted in science

sourced worldwide

LianBio is a biotechnology company focused on bringing paradigm-shifting medicines to patients.


Scroll to see more



Our Mission

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.

Learn More


Our Future

We are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.

See All

Stay up to date

News & Events

June 2, 2021

Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets


May 17, 2021

Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets


May 12, 2021

Nanobiotix Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumore Types and Therapeutic Combinations in China and Other Asian Markets


May 10, 2021

LianBio Appoints Yizhe Wang, Ph.D., as Chief Executive Officer

See All

We are here for you

Contact Us

Email us directly:

IR@LianBio.com careers@lianbio.com

Office Addresses

Shanghai Office
9th Floor, Kerry Parkside, 1155 Fangdian Road
Unit 901-902
Shanghai, PRC 201204

New Jersey Office
103 Carnegie Center Drive
Suite 215
Princeton, NJ 08540